After 12 evaluable patients have accrued to arm A, enrollment to arm B will begin. After 12 evaluable patients have accrued to arm B, enrollment to arm C will begin. 2.4 BASELINE EVALUATION All subjects are required to complete baseline evaluations within 14 days prior to the first planned dosing of the study drug (any screening evaluation done within this 14-day time period can also serve for the baseline evaluation unless otherwise indicated): Medical history and physical exam including weight, ECOG performance status and vital signs CT scan of the neck and chest (within 28 days prior to first dosing of study drug). Concomitant medications and baseline signs and symptoms evaluation EKG Serum pregnancy test (β-HCG) for females of childbearing-potential and women < 12 months since the onset of menopause (within 3 days prior to study therapy) Serum Chemistries: oAcute care panel (Na+, K+, Cl-, total CO2, creatinine, glucose, blood urea nitrogen) oHepatic panel (AST/GOT, ALT/GPT, total bilirubin, direct bilirubin oMineral panel (albumin, calcium total, magnesium total, phosphorus) Thyroid tests: TSH, free T3 and T4, Lipase, amylase, LDH, GGT Hematology: CBC with differential and platelets, PT, PTT TBNK phenotyping Urinalysis CK, Uric Acid, Total Protein, CRP HLA class I profile (any time prior to study treatment initiation) and may be deferred if it has previously been performed at the NIH. For correlative studies: Blood and tissue sample will be collected.